AU2007319014B2 - Novel compounds and methods for their production - Google Patents

Novel compounds and methods for their production Download PDF

Info

Publication number
AU2007319014B2
AU2007319014B2 AU2007319014A AU2007319014A AU2007319014B2 AU 2007319014 B2 AU2007319014 B2 AU 2007319014B2 AU 2007319014 A AU2007319014 A AU 2007319014A AU 2007319014 A AU2007319014 A AU 2007319014A AU 2007319014 B2 AU2007319014 B2 AU 2007319014B2
Authority
AU
Australia
Prior art keywords
ansamycin
strain
conh
analogue
geldanamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007319014A
Other languages
English (en)
Other versions
AU2007319014A1 (en
Inventor
Christine Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0622342.4A external-priority patent/GB0622342D0/en
Priority claimed from GB0720875A external-priority patent/GB0720875D0/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2007319014A1 publication Critical patent/AU2007319014A1/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY Request for Assignment Assignors: BIOTICA TECHNOLOGY LIMITED
Application granted granted Critical
Publication of AU2007319014B2 publication Critical patent/AU2007319014B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2007319014A 2006-11-09 2007-11-09 Novel compounds and methods for their production Ceased AU2007319014B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0622342.4 2006-11-09
GBGB0622342.4A GB0622342D0 (en) 2006-11-09 2006-11-09 Novel compounds and methods for their production
GB0720875.4 2007-10-24
GB0720875A GB0720875D0 (en) 2007-10-24 2007-10-24 Novel compounds and methods for their production
PCT/GB2007/050679 WO2008056188A2 (en) 2006-11-09 2007-11-09 Novel compounds and methods for their production

Publications (2)

Publication Number Publication Date
AU2007319014A1 AU2007319014A1 (en) 2008-05-15
AU2007319014B2 true AU2007319014B2 (en) 2013-03-28

Family

ID=39362724

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007319014A Ceased AU2007319014B2 (en) 2006-11-09 2007-11-09 Novel compounds and methods for their production

Country Status (10)

Country Link
US (1) US8492370B2 (cg-RX-API-DMAC10.html)
EP (1) EP1973883B1 (cg-RX-API-DMAC10.html)
JP (1) JP2010509306A (cg-RX-API-DMAC10.html)
KR (1) KR20090075856A (cg-RX-API-DMAC10.html)
AU (1) AU2007319014B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0718564A2 (cg-RX-API-DMAC10.html)
CA (1) CA2669047A1 (cg-RX-API-DMAC10.html)
ES (1) ES2389740T3 (cg-RX-API-DMAC10.html)
MX (1) MX2009004775A (cg-RX-API-DMAC10.html)
WO (1) WO2008056188A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
KR101097850B1 (ko) 2009-02-24 2011-12-23 한국생명공학연구원 젤다나마이신 생합성 조절유전자 변이주 및 이를 이용한 젤다나마이신 생산방법
CN117695374B (zh) * 2024-01-25 2024-09-06 超越健康科技(浙江)有限公司 一种用于治疗帕金森病的生物药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061461A1 (ja) * 2003-12-24 2005-07-07 Kyowa Hakko Kogyo Co., Ltd. ヒートショックプロテイン90（hsp90）ファミリー蛋白質阻害剤
AU2006263111A1 (en) * 2005-06-29 2007-01-04 Kyowa Hakko Kirin Co., Ltd. Benzenoid ansamycin derivative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9401936D0 (en) * 1992-01-06 1994-09-28 Pfizer Process and uses for 4,5-diohydrogeldanamycin and its hydroquinone
US7465718B2 (en) * 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
WO2007074347A1 (en) 2005-12-24 2007-07-05 Biotica Technology Ltd. 21-deoxymacbecin analogues useful as antitumor agents
CN101012196A (zh) * 2006-12-27 2007-08-08 中国人民解放军军事医学科学院毒物药物研究所 芳香化格尔德霉素类衍生物及其制备方法和用途
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061461A1 (ja) * 2003-12-24 2005-07-07 Kyowa Hakko Kogyo Co., Ltd. ヒートショックプロテイン90（hsp90）ファミリー蛋白質阻害剤
AU2006263111A1 (en) * 2005-06-29 2007-01-04 Kyowa Hakko Kirin Co., Ltd. Benzenoid ansamycin derivative

Also Published As

Publication number Publication date
ES2389740T3 (es) 2012-10-31
AU2007319014A1 (en) 2008-05-15
KR20090075856A (ko) 2009-07-09
US20110021481A1 (en) 2011-01-27
EP1973883B1 (en) 2012-07-11
WO2008056188A3 (en) 2008-07-31
BRPI0718564A2 (pt) 2014-03-11
JP2010509306A (ja) 2010-03-25
CA2669047A1 (en) 2008-05-15
WO2008056188A2 (en) 2008-05-15
MX2009004775A (es) 2009-05-21
US8492370B2 (en) 2013-07-23
EP1973883A2 (en) 2008-10-01

Similar Documents

Publication Publication Date Title
US20090209494A1 (en) 21-deoxymacbecin analogues useful as antitumor agents
US20090253667A1 (en) 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
US20100068203A1 (en) 17-Oxymacbecin Derivatives and Their Use in the Treatment of Cancer and/or B-Cell Malignancies
EP1973883B1 (en) Novel compounds and methods for their production
US20110160175A1 (en) 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
US20090117127A1 (en) Novel Compounds and Methods for Their Production
US20090209507A1 (en) 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20110091452A1 (en) 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20090298804A1 (en) Novel Compounds and Methods for Their Production
US20100210597A1 (en) C21-Deoxy Ansamycin Derivatives as Antitumor Agents
EP2079700A1 (en) 18, 21-didesoxymacbecin derivatives for the treatment of cancer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BRISTOL-MYERS SQUIBB COMPANY

Free format text: FORMER APPLICANT(S): BIOTICA TECHNOLOGY LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired